Stockscreener 앱 받기
19.65
0.00%
0.00
시간 외 거래:
19.50
-0.15
-0.76%
전일 마감가:
$19.65
열려 있는:
$19.65
하루 거래량:
2.82M
Relative Volume:
1.37
시가총액:
$6.84B
수익:
$3.05B
순이익/손실:
$181.32M
주가수익비율:
52.68
EPS:
0.373
순현금흐름:
$186.11M
1주 성능:
-2.09%
1개월 성능:
+15.25%
6개월 성능:
+54.60%
1년 성능:
+87.50%
1일 변동 폭
$18.97
$19.71
1주일 범위
$18.97
$20.60
52주 변동 폭
$9.56
$21.18
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
19.65 | 6.89B | 3.05B | 181.32M | 186.11M | 0.373 |
TAK
Takeda Pharmaceutical Co Adr
|
18.52 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.25 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.08 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
532.78 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | UBS | Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
UBS reiterates Amneal Pharmaceuticals stock Buy rating on HRT growth By Investing.com - Investing.com UK
A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.7% Gain -- G - GuruFocus
Amneal Pharmaceuticals' Biosimilars, Specialty Growth Reshape Earnings Profile, Oppenheimer Says - marketscreener.com
Oppenheimer initiates Amneal Pharmaceuticals stock with outperform rating By Investing.com - Investing.com Nigeria
Oppenheimer initiates Amneal Pharmaceuticals stock with outperform rating - Investing.com
Oppenheimer Initiates Amneal Pharmaceuticals at Outperform With $27 Price Target - Yahoo Finance
Form 4 Amneal Pharmaceuticals Inc Class A For: 23 September By Investing.com - Investing.com Canada
Form 4 Amneal Pharmaceuticals Inc Class A For: 23 September - Investing.com India
Amneal Pharmaceuticals, Inc. (AMRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Amneal Pharmaceuticals, Inc. (AMRX) stock price, news, quote and history - Yahoo Finance UK
Form 4 Amneal Pharmaceuticals Inc Class A For: 22 September By Investing.com - Investing.com Nigeria
Amneal: Even My Bull Case Barely Justifies $20/Share (NASDAQ:AMRX) - Seeking Alpha
Amneal Pharmaceuticals Inc (AMRX) Shares Surge 7.8% -- What GF S - GuruFocus
Amneal Pharmaceuticals Director Kevin J. Buchi Transfers 20,445 Shares to Trust - Kalkine Media
Why Is Amneal (AMRX) Stock Rocketing Higher Today - Yahoo Finance
Amneal (NASDAQ: AMRX) director gifts 20,445 shares to trust he oversees - Stock Titan
Amneal Pharmaceuticals Jumps 6.4% After Barclays Maintains Overweight - AlphaStreet
Update: Amneal Pharmaceuticals Shares Rise After FDA Approval for Lanreotide Injection - Yahoo Finance
Amneal Pharmaceuticals stock hits 52-week high at 19.32 USD - Investing.com
Amneal Pharmaceuticals stock hits 52-week high at 19.32 USD By Investing.com - Investing.com Australia
Amneal Launches Its Generic Lanreotide Immediately While the Brand Still Posts Nearly a Billion in US Sales - Medical Daily
Amneal Pharmaceuticals stock gains after FDA approval for lanreotide injection - ad-hoc-news.de
Amneal receives FDA approval for generic lanreotide injection By Investing.com - Investing.com Nigeria
AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod - Yahoo Finance
Stocks to Watch : Paramount Skydance, Warner Bros. Discovery, Accenture, Amneal Pharmaceuticals - marketscreener.com
Amneal Pharmaceuticals Secures FDA Approval for Lanreotide Injection - finance.yahoo.com
Amneal receives FDA approval for generic lanreotide injection - Investing.com
An injection for three conditions launches immediately after FDA approval - Stock Titan
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains? - Eastern Progress
Amneal Pharmaceuticals Inc. (AMRX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Amneal Pharmaceuticals Inc (AMRX) Stock Down 3.3% but Still Over - GuruFocus
Insider Unloading: KEVIN BUCHI Sells Options, Realizes $54K - Benzinga
Kentucky Gov. Andy Beshear visits Amneal's Glasgow facility - goSkagit
Amneal Pharmaceuticals, Inc.Class A Common Stock (NQ: AMRX - The Chronicle-Journal
Leerink Partners Initiates Coverage on Amneal Pharmaceuticals With Outperform, $23 Price Target - marketscreener.com
Does Amneal’s New US$523 Million Shelf Registration Reframe Its Capital Allocation Story for AMRX? - simplywall.st
Does Amneal’s Post‑Earnings Shelf Registration Reshape the Bull Case for Amneal Pharmaceuticals (AMRX)? - Yahoo Finance
Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats - Yahoo Finance
Amneal Pharmaceuticals (AMRX) Stock Sees Modest Fair Value Lift On Launch Optimism - Yahoo Finance
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns - Reuters
Amneal Pharmaceuticals files prospectus for sale of up to 28.9 million shares - scanx.trade
Amneal Pharmaceuticals (AMRX) Following Its Biosimilars Push And The Fair Value Debate - simplywall.st
Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX) - Yahoo Finance
Amneal Pharmaceuticals Says US FDA Approves Romidepsin Injection Solution - Moomoo
J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Amneal builds end-to-end biosimilars capacity in the U.S. - Chain Drug Review
Amneal Pharmaceuticals (AMRX) Stock Looks Fairly Valued But Earnings Still Look Rich - sahmcapital.com
Amneal (AMRX) Results Review: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction: The Share Price Adds 1.87% in the Current UpdateProfit Warning Alert - Vinanet
Amneal (AMRX) Earnings Report: EPS Beats Its Estimate in Latest Trading; The Market Price Declines 1.25% in the Latest SessionDiluted EPS Report - vinanet.vn
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm - Business Wire
Zacks.com featured highlights include CareDx, Healthcare Services, Forum Energy Tech, Amneal Pharma and Caterpillar - Yahoo Finance
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Amneal Pharmaceuticals Inc 주식 (AMRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kiely John | Director |
Aug 13 '26 |
Sale |
17.64 |
50,000 |
882,000 |
210,252 |
| Shah Nikita | Executive Vice President |
Aug 12 '26 |
Sale |
17.51 |
146,403 |
2,563,517 |
253,390 |
| Daly Jason B. | EVP, Chief Legal Officer |
Aug 12 '26 |
Sale |
17.40 |
210,000 |
3,654,000 |
35,171 |
| Daly Jason B. | EVP, Chief Legal Officer |
Aug 11 '26 |
Sale |
17.70 |
6,613 |
117,050 |
245,171 |
0.57%
0.81%
자본화:
|
볼륨(24시간):